References
- 1
Aston-Jones G, Harris GC.
Brain substrates for increased drug seeking during protracted withdrawal.
Neuropharmacology.
2004;
47
((Suppl. 1))
167-179
- 2
Bailey CP, Mollemann A, Little HJ.
Comparison of the effects of drugs on hyperexitability induced in hippocampal slices
by withdrawal from chronic ethanol consumption.
Br J Pharmacol.
1998;
123
215-222
- 3
Bonnet U, Banger M, Leweke FM. et al .
Treatment of alcohol withdrawal syndrome with gabapentin.
Pharmacopsychiatry.
1999;
32
107-109
- 4
Dooley DJ, Donovan CM, Pugsley TA.
Stimulus-dependent modulation of [(3) H] norepinephrine release from rat neocortical
slices by gabapentin and pregabalin.
J Pharmacol Exp Ther.
2000;
295
1086-1093
- 5
Gatch MB, Lal H.
Pharmacological treatment of alcoholism.
Prog Neuropsychopharmacol Biol Psychiatry.
1998;
22
917-944
- 6
Kosten TR, O’Conner PG.
Management of drug and alcohol withdrawal.
N Engl J Med.
2003;
348
1786-1795
- 7
Krystal JH, Petrakis IL, Mason G. et al .
N-Methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment,
and vulnerability.
Pharmacol Ther.
2003;
99
79-94
- 8
Satel SL, Kosten TR, Schuckit MA. et al .
Should protracted with-drawal from drugs be included in DSM-IV?.
Am J Psychiatry.
1993;
150
695-704
- 9
Sullivan JT, Sykora K, Schneiderman J.
Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment
for alcohol scale (CIWA-Ar).
Br J Addiction.
1989;
84
1353-1357
Correspondence
Prof. Dr. med. U. Bonnet
Rheinische Klinken Essen
Klinik für abhängiges Verhalten und Suchmedizin & Klinik für Psychiatrie und Psychotherapie
Universität Duisburg/Essen
Virchowstr. 174
45147 Essen
Germany
Email: udo.bonnet@lvr.de
